Christophe Bourdon, LEO Pharma CEO, on Dermatology Innovation, Rare Disease & Scalable Growth

Hello and welcome to the BioTech 2,050 podcast. BioTech 2,050 is a think tank chronicling the disruptions changing the biotech industry over the next several decades. Check out our website at biotech2050.com. I'm today's cohost, Alok Tahey. I'm the CEO and cofounder of Vibe Bio. Vibe is an AI platform focused on the biotech industry. We're really excited today to be joined by Christophe Pordon, the CEO of LEO Pharma. We're at JPM and having a really interesting set of discussions about what's going on in biotech, people's growth plans, and what the future looks like for our industry. Christophe, thanks so much for joining us. Thank you so much. You know, maybe to kick it off, would love if you can give us just a couple quick words on your background as well as Leo as a whole. Yeah. Christophe, I basically worked three years in the industry at Sanofi, at Alexion, and then at Amgen. And really with one strong conviction that Briggsy basically bringing the promise of innovation and translating this into a benefit for patients is something that is really rewarding. It's rewarding personally, it's rewarding for patient, and it's rewarding often financially if you do it in the right way. I've seen at Alexion for three years, you know, the wonder of of rare disease, what you can do, really focusing on one patient at a time. And I've seen at Amgen, you know, in oncology, both internationally and in The US, how you can basically save lives. And this has been very inspiring. And this is exactly with the same promise that I joined LEO Pharma. LEO has been a company focusing on medical dermatology, so skin disease for sixty years. And I was convinced that this is a place where you could also bring, you know, transforming and help bringing the hope of innovation and make a fundamental difference for patient affected by skin diseases. You know, maybe we'd love to just to sort of learn a little bit more about kind of both the pipeline, the programs that you're most excited about. I feel like the interesting thing about being a commercial stage company is the opportunity to sort of span and see both the innovation on the horizon, but also see the impact to patients today with the programs and the drugs that you've already marketed. Love to just hear an overview of, of course. At Liu is we have basically sixty years of experience in track record in dermatology, and we are serving 100,000,000 patients across the globe. We have a unique platform, unique expertise, serving patients in 70 countries. And so the question was, okay, how can we leverage that platform and add additional innovation? What's fascinating in medical dermatology is it's basically one third of the global population is affected by skin disease. Sometimes it's rare, sometimes it's very prevalent, sometimes it's very painful. So you have a very broad spectrum of disease. And thousand of disease have …